JP2025510700A - Ｔｒｏｐ－２を発現する腫瘍を標的化するための抗体コンジュゲート - Google Patents

Ｔｒｏｐ－２を発現する腫瘍を標的化するための抗体コンジュゲート Download PDF

Info

Publication number
JP2025510700A
JP2025510700A JP2024556005A JP2024556005A JP2025510700A JP 2025510700 A JP2025510700 A JP 2025510700A JP 2024556005 A JP2024556005 A JP 2024556005A JP 2024556005 A JP2024556005 A JP 2024556005A JP 2025510700 A JP2025510700 A JP 2025510700A
Authority
JP
Japan
Prior art keywords
group
antibody
hetero
moiety
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510700A5 (enExample
Inventor
アントニア ウェイデーヴェン，マリア
ゲール，レモン ヴァン
ベルケル，サンダー セバスチャン ヴァン
デルフト，フローリス ルイス ヴァン
レリーベルト，リアン
Original Assignee
シンアフィックス ビー．ブイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンアフィックス ビー．ブイ． filed Critical シンアフィックス ビー．ブイ．
Publication of JP2025510700A publication Critical patent/JP2025510700A/ja
Publication of JP2025510700A5 publication Critical patent/JP2025510700A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024556005A 2022-03-23 2023-03-23 Ｔｒｏｐ－２を発現する腫瘍を標的化するための抗体コンジュゲート Pending JP2025510700A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22163943.8 2022-03-23
EP22163943 2022-03-23
PCT/EP2023/057561 WO2023180485A1 (en) 2022-03-23 2023-03-23 Antibody-conjugates for targeting of tumours expressing trop-2

Publications (2)

Publication Number Publication Date
JP2025510700A true JP2025510700A (ja) 2025-04-15
JP2025510700A5 JP2025510700A5 (enExample) 2026-03-31

Family

ID=81308125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556005A Pending JP2025510700A (ja) 2022-03-23 2023-03-23 Ｔｒｏｐ－２を発現する腫瘍を標的化するための抗体コンジュゲート

Country Status (10)

Country Link
US (1) US20250090679A1 (enExample)
EP (1) EP4496594A1 (enExample)
JP (1) JP2025510700A (enExample)
KR (1) KR20250024743A (enExample)
CN (1) CN119212731A (enExample)
AU (1) AU2023241225A1 (enExample)
CA (1) CA3253220A1 (enExample)
IL (1) IL315207A (enExample)
MX (1) MX2024011520A (enExample)
WO (1) WO2023180485A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020094670A1 (en) 2018-11-05 2020-05-14 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
IL315366A (en) 2022-03-23 2024-11-01 Synaffix Bv Antibody pairs for targeting PTK7-expressing tumors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939255A (en) 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
ATE265532T1 (de) 1995-10-19 2004-05-15 Bristol Myers Squibb Co Monoklonaler antikörper br110 und dessen anwendung
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
WO2008029281A2 (en) 2006-02-10 2008-03-13 Invitrogen Corporation Labeling and detection of post translationally modified proteins
US20080131428A1 (en) 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US7420041B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
WO2009102820A2 (en) 2008-02-11 2009-08-20 Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services Modified sugar substrates and methods of use
CA2750038C (en) 2009-02-05 2016-10-04 Oncoxx S.R.L. Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
JPWO2011155579A1 (ja) 2010-06-10 2013-08-15 北海道公立大学法人 札幌医科大学 抗Ｔｒｏｐ−２抗体
US8871908B2 (en) 2011-11-11 2014-10-28 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
ES2659270T5 (en) 2012-10-23 2026-02-11 Synaffix Bv Modified antibody, antibody-conjugate and process for the preparation thereof
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
PT3088419T (pt) 2013-12-25 2019-01-11 Daiichi Sankyo Co Ltd Conjugado de anticorpo anti-trop2-fármaco
KR20170030648A (ko) 2014-08-04 2017-03-17 시나픽스 비.브이. 베타-(1,4)-n-아세틸갈락토오스아미닐트랜스퍼라아제, 또는 이의 돌연변이체를 이용한 당 단백질의 변형 방법
ES2740907T3 (es) 2014-10-03 2020-02-07 Synaffix Bv Enlazador de sulfamida, conjugados de los mismos y métodos de preparación
HUE038511T2 (hu) 2015-04-23 2018-10-29 Synaffix Bv (1,4)-N-acetil-galaktóz-aminil-transzferáz vagy (1,4)-N-acetil-galaktóz-aminil-transzferázból származó glikoziltranszferázt alkalmazó, glikoprotein módosítására szolgáló eljárás
WO2017214491A1 (en) 2016-06-09 2017-12-14 Blinkbio, Inc. Silanol based therapeutic payloads
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
WO2020094670A1 (en) * 2018-11-05 2020-05-14 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
CR20210541A (es) 2019-03-29 2021-12-20 Medimmune Ltd Compuestos y conjugados de estos
HUE065484T2 (hu) 2019-04-26 2024-05-28 Immunogen Inc Camptothecin-származékok
CN116209679A (zh) 2020-06-05 2023-06-02 财团法人生物技术开发中心 含有抗间皮素抗体的抗体-药物共轭物及其用途
NL2026947B1 (en) 2020-11-20 2022-07-01 Synaffix Bv Tyrosine-based antibody conjugates
CN113816969B (zh) 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用
JP7451677B2 (ja) 2021-07-19 2024-03-18 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 二成分毒素を担った抗体薬物複合体及びその応用

Also Published As

Publication number Publication date
WO2023180485A1 (en) 2023-09-28
EP4496594A1 (en) 2025-01-29
CN119212731A (zh) 2024-12-27
MX2024011520A (es) 2025-01-09
AU2023241225A1 (en) 2024-08-29
CA3253220A1 (en) 2023-09-28
US20250090679A1 (en) 2025-03-20
IL315207A (en) 2024-10-01
KR20250024743A (ko) 2025-02-19

Similar Documents

Publication Publication Date Title
US20260108620A1 (en) Antibody-conjugates for targeting of tumours expressing trop-2
US20250082770A1 (en) Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
US12440573B2 (en) Antibody-conjugates for targeting of tumours expressing PTK7
JP2021524852A (ja) 抗ｍｕｃ１抗体−薬物コンジュゲート
US20260115308A1 (en) Anti-her2 antibody-drug conjugates and uses thereof
US20250090679A1 (en) Antibody-conjugates for targeting of tumours expressing trop-2
KR20230137339A (ko) B7h4-표적화된 항체-약물 접합체 및 이의 사용 방법
JP2023510349A (ja) ペプチド含有リンカーとの部位特異的抗体－薬物コンジュゲート
US20260007761A1 (en) Bioactive Conjugate, Preparation Method Therefor and Use Thereof
JP2024532304A (ja) 抗体－薬物コンジュゲートを使用する方法
CN119604314A (zh) 抗gd2抗体、免疫偶联物及其治疗用途
US20250205353A1 (en) Antibody-conjugates for targeting of tumours expressing nectin-4
JP2024529466A (ja) 抗体薬物コンジュゲート及びその使用方法
JP2024503075A (ja) 抗体－薬物コンジュゲートのための二重切断エステルリンカー
TW202434739A (zh) 用於抗體藥物複合體工程之糖苷合成酶變體
JP2022552349A (ja) Ｂリンパ球特異的アマトキシン抗体コンジュゲート
EP4541376A1 (en) Antibody-drug conjugates
JP7689606B2 (ja) ネクチン－４抗体及び抗体－薬物コンジュゲート
TW202434311A (zh) 自穩定連接子軛合物
JP2025526869A (ja) アントラサイクリン及びそのコンジュゲート
HK40123391A (zh) 抗gd2抗体、免疫偶联物及其治疗用途
HK40094183A (zh) 具有溶解性标签的分子和相关方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260323